Get the Stockscreener App
163.88
1.37%
-2.385
Charles River Laboratories International Inc stock is traded at $163.88, with a volume of 248.71K.
It is down -1.37% in the last 24 hours and down -13.58% over the past month.
See More
Previous Close:
$166.27
Open:
$166.85
24h Volume:
248.71K
Relative Volume:
0.34
Market Cap:
$9.72B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
20.46
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
-0.47%
1M Performance:
-13.58%
6M Performance:
-17.99%
1Y Performance:
-24.97%
1-Day Range:
$163.33
$166.85
1-Week Range:
$160.00
$169.67
52-Week Range:
$159.65
$275.00
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
163.99 | 9.72B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
566.83 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
206.90 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
145.18 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
457.67 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
207.38 | 36.97B | 15.32B | 1.41B | 1.96B | 7.62 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Rating of "Reduce" by Brokerages - MarketBeat
Morgan Stanley Lowers Charles River Laboratories International (NYSE:CRL) Price Target to $184.00 - Defense World
E. Ohman J or Asset Management AB Buys 1,800 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Trust Point Inc. Acquires Shares of 2,045 Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Morgan Stanley Adjusts Charles River Laboratories International's Price Target to $184 From $220 - Marketscreener.com
SG Americas Securities LLC Sells 554 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
Charles River Laboratories International (CRL) Expected to Announce Earnings on Wednesday - Defense World
JPMorgan Chase & Co. Has Lowered Expectations for Charles River Laboratories International (NYSE:CRL) Stock Price - Defense World
Charles River Laboratories stock hits 52-week low at $160.73 - MSN
Boston Trust Walden Corp Purchases 8,338 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
JPMorgan Chase & Co. Issues Pessimistic Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Norris Perne & French LLP MI - MarketBeat
CRL Gears Up for Q4 Earnings: Here's What You Need to Know - MSN
Short Interest in Charles River Laboratories International, Inc. (NYSE:CRL) Rises By 5.6% - Defense World
Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month LowShould You Sell? - MarketBeat
Laurus Investment Counsel Inc. Has $14.61 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Stock Position Lowered by Hantz Financial Services Inc. - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Janney Montgomery Scott LLC - MarketBeat
Charles River Laboratories: Retained Earnings, ROE, And Debt Management Will Shape Its Future Amid Weak Demand - Seeking Alpha
High Throughput Screening (HTS) Market to Grow by USD 19.9 Billion (2024-2028), Boosted by Rising R&D Investments, with AI Redefining Market LandscapeTechnavio - Yahoo Finance
Pharma researcher Charles River to close Durham facility, lay off dozens - WRAL News
Fifth Third Bancorp Sells 3,752 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Gmp Cell Banking Services Market Generated Opportunities, - openPR
Charles River Laboratories credit outlook lowered to stable at S&P on weak 2025 guidance - MSN
Clinical Trials Market Outlook: Competitor Insights and Market - openPR
Billion-dollar pharma company to close Triangle sites - The Business Journals
Charles River Laboratories stock hits 52-week low at $160.73 By Investing.com - Investing.com Canada
Janney Montgomery Scott LLC Has $7.26 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
CRLCharles River Laboratories International, Inc. Latest Stock News & Market Updates - StockTitan
Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call - sharewise
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Mizuho starts Charles River Labs at neutral, cites near-term challenges - MSN
Atomi Financial Group Inc. Has $298,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
We Think Charles River Laboratories International (NYSE:CRL) Is Taking Some Risk With Its Debt - Simply Wall St
The Goldman Sachs Group Has Lowered Expectations for Charles River Laboratories International (NYSE:CRL) Stock Price - Defense World
Charles River Laboratories' Quarterly Earnings Preview: What You Need to Know - MSN
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
The Goldman Sachs Group Issues Pessimistic Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price - MarketBeat
Charles River Laboratories' Quarterly Earnings Preview: What You Need To Know - Barchart
Veracity Capital LLC Acquires New Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line? - MSN
Park Avenue Securities LLC Has $514,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
William Blair Downgrades Charles River Laboratories International (NYSE:CRL) to Market Perform - Defense World
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises - MSN
What Analysts Are Saying About Charles River Stock - Benzinga
Riverbridge Partners LLC Decreases Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Pharmaceutical Regulatory Affairs Research Report 2025-2030: Entry of Companies into the Global Market Fueling Growth - GlobeNewswire Inc.
Charles River downgraded to Market Perform from Outperform at William Blair - Yahoo Finance
Cell Bank Creation Service Market Overall Study Report - openPR
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.26%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):